TransCode Therapeutics Inc. (RNAZ) - Forward Price-to-Revenue Multiple
RNA therapy developments for cancer treatment are currently in the testing phase, with financial stability sustained solely by shareholder investments. TransCode Therapeutics (RNAZ) is creating innovative methods for delivering molecules into tumors for future monetization through patents. The absence of commercial products and high R&D expenditures render cash flow unpredictable. The forward P/S multiple reflects the market's reaction to forecasts, where the mark captures this metric.
Comprehensive metric breakdowns and analytics for transcodetherapeutics.com (RNAZ)
- stock price and consensus target price:
- market capitalization indicators:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity TransCode Therapeutics|RNAZ - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital TransCode Therapeutics, Inc.|RNAZ - Company Aggregate Debts|Debt to Book Capitalization Ratio TransCode Therapeutics|RNAZ - Long-Term Liabilities|Company Short-Term Debts TransCode Therapeutics|Quick Liquidity Indicator transcodetherapeutics.com
- financial results and valuation multiples details:
RNAZ - Net Profit|Future Profit TransCode Therapeutics|RNAZ - Market Price to Net Income Ratio|Forward P/E Multiple TransCode Therapeutics, Inc.|RNAZ - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple TransCode Therapeutics|RNAZ - Operating profit before deduction of amortization|Earnings per share for the last twelve months TransCode Therapeutics|RNAZ - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months transcodetherapeutics.com|RNAZ - Earnings per share increase in current year|Net earnings per share growth forecast for next year TransCode Therapeutics
- company sales and revenue statistics:
Fundamental company analysis:RNAZ (TransCode)
Forward P/S measures the market value of a business relative to projected sales volume, allowing for an objective assessment of capitalization adequacy for potential M&A transactions. Analyzing the projected price-to-sales ratio helps investors avoid overpaying, which is critical for TransCode Therapeutics (RNAZ), whose unique nanotransporters in oncology create high added value and protect the company from competitive pricing pressure.
Direct competitors
Tempus AI, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales QGEN|IONS: Forward Price-to-Revenue Multiple|Repligen Inc. - Price to Expected Revenue Ratio|RNA: Forward P/S Multiple|crisprtx.com - Forward Price to Sales|WGS (GeneDx) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ultragenyx Pharmaceutical Inc. RARE|Price-to-Projected Revenue Ratio Beam Therapeutics Corp (BEAM)|SRPT (Sarepta Corp) - Forward Price to Sales|Forward P/S Multiple TWST (Twist Bioscience)|Forward P/S Multiple 10xgenomics.com TXG|NTLA - Price-to-Projected Revenue Ratio|Future Price to Revenue STOK|BLFS: Forward P/S Multiple|Market Cap to Future Revenue Ratio Wave Pharma (WVE)|Forward Price-to-Revenue Multiple MAZE|Forward P/S Multiple sionnatx.com|Forward Price-to-Revenue Multiple PRME (Prime Medicine)|Price to Expected Revenue Ratio TSHA|Forward P/S Multiple QURE (uniQure Corp)|Market Cap to Expected Sales Ratio MeiraGTx Corp (MGTX)|REGENXBIO Inc. - Forward P/S Multiple|solidbio.com (SLDB) - Forward Price-to-Revenue Multiple|Ocugen (OCGN) - Price-to-Projected Revenue Ratio|PACB - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Benitec|DSGN: Forward Price to Sales|Price-to-Projected Revenue Ratio Rocket Pharmaceuticals (RCKT)|4dmoleculartherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple LXEO (Lexeo Therapeutics, Inc.)|Forward P/S Multiple Korro Bio Inc. KRRO|EDIT: Forward Price-to-Revenue Multiple|Future Price to Revenue SLN|PRQR: Forward P/S Multiple|Market Cap to Projected Revenue CDXS|Price-to-Projected Revenue Ratio Sangamo Therapeutics, Inc.|Market Cap to Projected Revenue NAUT (Nautilus Biotechnology Inc)|Forward P/S Multiple MGX|Forward P/S Multiple Precision BioSciences Inc. (DTIL)|Generation Bio - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio BOLD (boundlessbio.com)|XCUR - Price-to-Projected Revenue Ratio|Forward Price to Sales IMNN (Imunon, Inc.)|PHIO: Forward P/S Multiple|Mustang Bio (MBIO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Bionano Genomics Inc.|Market Cap to Projected Revenue APDN (adnas.com)|Price-to-Projected Revenue Ratio bluebird bio (BLUE)|Market Cap to Expected Sales Ratio immunoprecise.com|Forward P/S Multiple OMGA (Omega)|OMIC - Forward Price-to-Revenue Multiple|RGLS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio syros.com|TBIO: Forward P/S Multiple|Market Cap to Projected Revenue TCON|UBX (Unity Bio) - Forward P/S Multiple
